term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patientsHighlights  3TC+DTG in simplification showed high efficacy.
Introduction
Combination antiretroviral therapy (cART) has dramatically decreased morbidity and mortality of the HIV-1infected population, 1 and a prompt initiation of cART has demonstrated to be fundamental in reducing the burden of serious AIDS and non-AIDS related events, independently from CD4 cell counts. 2 However, mathematical models forecast that in next few decades age-related comorbidities will become a substantial issue in HIV-infected individuals, 3 especially due to an increased burden of cardiovascular diseases, diabetes and chronic kidney disease. Moreover, the indication to treat all HIV-1-infected patients regardless of CD4 count 4 raises the concern of the long-term treatment-related toxicities (especially those related to nucleoside reverse transcriptase inhibitors, NRTIs) 5 and patients' adherence. 4, 6 Finally, the increasing prevalence of HIV infection, of life expectancy of the infected population, and of projected lifetime healthcare costs also prompt the need for new treatment paradigms. 7 In selected patients, treatment simplification with two-drug regimens after achieving a stable virological suppression represents one of the recommended switch strategies in treatment guidelines. 4, 8 Among these strategies, in the recent past, lamivudine with boosted protease inhibitors (bPIs), [9] [10] [11] [12] and particularly with atazanavir, 10, 11 has shown the most robust data in terms of efficacy and safety. However, given the toxicity of bPIs, their impact on the individual's metabolic profile [9] [10] [11] [12] and the potential for drug-drug interactions determined by the boosting agents, 13 new switch strategies have emerged. Results from clinical trials and observational studies [14] [15] [16] [17] [18] [19] suggest that lamivudine plus dolutegravir could be a safe and effective option as well as a very well tolerated one but long-term data are still lacking in literature.
We previously reported a single-center, long term analysis on 221 virologically suppressed switching to dolutegravir plus lamivudine patients with a median time of follow-up of 96 months. 20 Goal of the present study was to confirm our preliminary findings in a multicenter cohort of adult HIV-1-infected patients, unselected for any criteria except for virological suppression at the time of switch.
Materials and methods
1 Study design. This was a retrospective, observational study in which we enrolled HIV-1-infected patients from nine Italian clinical centers. Criteria for eligibility were: patient's informed consent to data collection, being at least 18 years-old, being on stable (i.e. at least 6 months) cART with viral suppression (HIV-RNA<50 copies/mL) at the moment of switch to lamivudine plus dolutegravir (baseline) and HBsAg negative. All patients switched for clinical reason to lamivudine plus dolutegravir, following the principles expressed by Italian Guidelines on the management of HIV infection. 21 2 Ethic statement. The study was performed according to the principles of the Declaration of Helsinki and received the approval by each independent local Ethics Committee (study coordination site protocol number 5284/15). All patients signed informed consent.
3 Statistical analysis. The primary study objective was to evaluate the time to virological failure (VF, defined by a single HIV-1 RNA ≥1,000 copies/mL or by two consecutive HIV-1 RNA ≥ 50 copies/mL) and the time to treatment discontinuation (TD, defined as the interruption of either 3TC or DTG) for any cause.
Survival analysis was employed to determine the time to TD and VF and the respective predictors were analyzed by Cox regression. Changes from baseline in immunological parameters (absolute and percentage CD4+ T-cell counts, CD4/CD8 ratio), estimated glomerular filtration rate (eGFR) (by the MDRD study equation), and blood lipids (total/HDL cholesterol ratio, triglycerides) at weeks 48, 96 and 144 were evaluated via linear mixed models for repeated measures. Linear regression was performed to explore variables associated to significant changes in laboratory parameters.
Results

Study population
Five-hundred fifty-six patients were eligible for the analysis: 391 (70.3%) were males, 125 (22.5%) were HCV-coinfected while 81 (14.6%) had a previous AIDS-defining event. Median age at baseline was 51.7 Two hundred twenty-six patients (40.6%) had experienced at least one virological failure; among them, 158 (69.9%) had more than 1 virological failure and median number of previous VF was 2 (IQR 1-4). Almost all of them (223/226, 98.7%) experienced at least one VF while in therapy with NRTIs and, in particular, 93 (41.1%) with TDF and 172 (76.1%) with 3TC. One hundred seventy-two patients (76.1%) had a VF while on a NNRTI, while 163 (72.1%) while in therapy with a PI (21 of which while on DRV). Finally, 9 (4.0%) experienced a VF while on a INI-based regimen (7 with RGV and 2 with EVG). Table 1 .
At the moment of switch, 224 (40.3%) patients were already on a dual ART (171 of whom with lamivudine plus bPI), while 307 (55.7%) were on a standard triple regimen with 2NRTIs and a third drug (141 with a NNRTI, 89 with an InSTI and 77 with a boosted PI). Fifty-two patients (9.4%) were on a regimen containing DTG before switching to the study regimen. Reasons for switching were mainly represented by simplification (27.9%), dyslipidemia (16.5%), gastro-intestinal toxicity (7.9%) or other toxicities (13.9%). Of note, the M184V resistance mutation to lamivudine was present in 45 (8.1%) patients in at least one previous genotypic resistance test.
Virological efficacy
The median follow-up time was 22.1 months (11.4-33.5). Twelve VF were detected over 1020.1 personyears of follow-up (PYFU) with an overall incidence of 1.2 VF per 100 PYFU. Seven of these patients discontinued 3TC+DTG: 4 were switched to a dolutegravir-based triple-regimen (2 with ABC/3TC and 2 with FTC/TDF), 2 were switched to FTC/TDF plus boosted DRV and 1 patient started ATV+DTG. The remaining five patients maintained study regimen. All of the patients experiencing VF re-achieved virologic control subsequently, while none of them developed resistance mutation after failure. The Kaplan-Meier curve for time to VF is shown in figure 1 . The estimated probability of maintaining virological suppression at weeks 48, 96 and 144 were 98.7% (SD ±0.5), 97.5% (SD ±0.8) and 96.5% (SD ±1.0), respectively. We found that years from HIV diagnosis were the only predictor of VF (aHR 1.1, 95% CI 1.1 -1.2, p=0.030) after adjusting for the presence of the M184V resistance mutation, time of virological suppression, nadir and baseline CD4+ cells count, HIV risk factor and switching from a PI-based regimen.
The presence of the M184V resistance mutation alone was not a predictor of VF; however, stratifying by time of virological suppression, we observed that, in patients with time of virological suppression < 88 months, the rate of VF was higher in the presence of the M184V mutation (6.7 per 100 PYFU vs 1.0 per 100 PYFU, Log-Rank p=0.014). Conversely, VF rates were not different in patients with time of virological suppression longer than 96 months, independently from M184V mutation (Log Rank p=0.308) ( Table 2 and Figure 1 ).
Treatment discontinuations
One hundred and ten treatment discontinuations occurred over 1025.6 PYFU (10.7 per 100 PYFU), with an estimated probability of remaining on lamivudine plus dolutegravir of 86.1% (SD ±1.5), 79.2% (SD ±1.9) and 75.2% (SD ±2.2) at weeks 48, 96 and 144, respectively. Median time to TD was 29.6 weeks (IQR 12.4-59.6).
Reasons for TD were represented by: virological failure (7 of 556, 1.3%), toxicity (43, 7.7%, of which 18 for neuropsychological events, 9 for gastrointestinal and hepatic toxicity, 6 for renal toxicity, 1 following a hypersensitivity reaction and 9 for other toxicities), further simplification to a single tablet regimen (7 cases, 1.3%), drug-drug interactions (2 cases, 0.4%), death (6, 1.1%) and other/unknown causes (41, 7.4%).
Among the 18 discontinuations caused by neuropsychological events, 8 were due to insomnia, 5 to headache, 3 to mood disorders and one was due to the sudden onset of nightmares. Of note, all of the adverse events leading to TD were of mild or moderate severity. Switching to study regimen for drug-drug interaction (vs switching for simplification, aHR 2.4, 95% CI 1.4-4.4, p=0.003) was a predictor of discontinuation, after adjusting for clinical center, years of HIV and HIV risk factor.
Evaluating discontinuations due to overall toxicity, the estimated probabilities of maintaining study regimen were 93.8% (SD ±1.1) at week 48, 91.4% (SD ±1.3) at week 96 and 90.4% (SD ±1.5). Switching to study regimen for toxicity (vs switching for simplification, aHR 3.1, 95% CI 1.4-6.9, p=0.006) was the only predictor of TD at a multivariate analysis, after adjusting for clinical center, HIV risk factor and a history of a previous dual regimen.
A specific survival analysis evaluating TD due only to neuropsychological events show that the estimated probabilities of remaining free from TD were 97.2% (SD ±0.7) at week 48 and 96.1% (SD ±0.9) at weeks 96 and 144 (Figure 2) . At a multivariate regression analysis, we found that HCV-coinfection (aHR 6.2, 95% CI 2.3-16.4, p<0.001) was a predictor of discontinuations due to CNS toxicity after adjusting for age, sex and previous cART. An increase in CD4/CD8 ratio was evidenced overall considering patients with available data at 96 weeks of follow-up with a significant difference in median change (+0.06, p=0.001). The trend was confirmed in the group of 46 patients with data at 144 weeks of follow-up, with a median change in CD4/CD8 ratio of +0.10 (p=0.002) (Figure 2a ). Evaluating the proportion of patients achieving a CD4/CD8 ratio ≥1, this was significantly higher both at 96 and 144 weeks of follow-up compared with baseline values; in particular, CD4/CD8 ratio was ≥1 in 39/125 patients (31.2%) at baseline and in 51/125 (40.8%) at 96 weeks (p<0.001).
Among patients with 144 weeks of follow-up, 13/53 (24.5%) had a CD4/CD8 ratio ≥1 at baseline while the proportion was significantly higher at 144 weeks (20/53, 37.7%, p<0.001). At a multivariate analysis, time of virological suppression was the only predictor of change in CD4/CD8 ratio both at 96 and 144 weeks. We observed a significant decrease in triglycerides' levels in patients with data at 96 (median change -10.8, p<0.001) and 144 weeks (-2.7, p=0.009) (Figure 2d) . Baseline values were predictive of a more pronounced improvement at both 96 (per 1 mg/dl more, -0.5, 95% CI -0.6 ; -0.3, p<0.001) and 144 weeks (per 1 mg/dl more, -0.8, 95% CI -0.9 ; -0.6, p<0.001), after adjusting for HIV risk factors and total cholesterol baseline levels.
Focusing on patients switching from 3TC + PI, we observed a more pronounced improvement in both total cholesterol levels and triglycerides at 144 weeks: in particular, we found a median decrease of total cholesterol of -19.0 mg/dL (p=0.036) and of triglycerides of -52.1 mg/dL (p=0.006).
As to the renal function, we observed a significant decrease in eGFR in patients with data at 96 weeks (median change -9.6 ml/min, p<0.001) and in those with data at 144 weeks (-5.2 ml/min, p<0.001). Baseline eGFR was related to a less marked decrease at both 96 (per 1 ml/min more, -0.3, 95% CI -0.4 ; -0.1, p<0.001) and 144 weeks (per 1 ml/min more, -0.3, 95% CI -0.5 ; -0.1, p<0.001); also, female sex (vs male sex, -7.4, 95% CI -13.1; -1.6, p=0.013) and coming from PI-based dual regimen (-5.4, 95% CI -10.7 ; -0.1, p=0.046) resulted protective at 96 weeks.
Discussion
Results from this multicenter study, conducted in a real-life setting, strengthen our previous monocentric work 20 with a large sample size (556 vs 221) and a longer follow-up time (1020.1 vs 419.7 PYFU) and confirm findings on the efficacy of a dual regimen of lamivudine and dolutegravir in virologically suppressed HIV1-infected patients. 14, 16, 17, 22 In particular, we observed a low rate of virological failures (an overall incidence of 1.2 VF per 100 PYFU) and an estimated probability of maintaining virological suppression of 96.5% at 144 weeks. It is to be noted, moreover, that none of the 12 patients experiencing virological failure developed resistance mutations to DTG or 3TC, a finding in line with what described by Joly et al, 16 further confirming the high genetic barrier of dolutegravir, 23 a characteristic that makes this drug suitable for a two-drug regimen. Regarding virological efficacy of this regimen, it is worth noting that data on patients' compliance to the regimen, a possible factor relating to HIV-RNA increases, were not collected in our study. Further insights are hence needed to assess the topic. Furthermore, the virological dynamics may be more thoroughly evaluated with studies aimed at evaluating the residual viremia and especially the viral reservoirs, first of all the HIV-DNA dosage, as already investigated in other two-drug regimens. 24 Our study also allows to frame the target of patients for whom this switch strategy may results more advantageous; in particular our data confirm that, even with a longer follow-up, the lone presence of the M184V resistance mutation is not a predictor of virological failure for this 3TC-containing dual regimen, probably because of the reduced replicative fitness caused to the virus by this mutation. [25] [26] [27] However, as previously reported by Gagliardini et al, 28 the M184V mutation appears to be associated with virological failure in patients with a reduced time of virological suppression at baseline. These results must bring to the attention of the clinician the need to collect a precise clinical and virological history of the patient before implementing a therapeutic simplification towards a two-drug regimen.
In our population we observed 110 discontinuations (19.8% of the total population), the majority of which (91) during the first 60 weeks of follow-up. Overall toxicity was the main reason for discontinuing study regimen (43 cases, 7.7% of our cohort) and, among those, the majority (18) were due to neuropsychological events. The rate of overall discontinuations appears in line with other studies on dolutegravir, 29 while it appears sensibly higher when compared to other cohorts. 22 This difference might be related to the longer follow-up time of our study, a unique finding not present in other works form the literature, that further reinforces our results. Focusing on CNS toxicity, a feature already described in other studies on DTG 29, 30 we reported that eighteen patients, the majority of which reported sleep disorders or a newly onset headache as the main problems, discontinued study regimen following these adverse events. The rate of discontinuations due to neuropsychological events appears higher compared to the cohort of Maggiolo et al, 22 in which just 2/218 patients discontinued 3TC+DTG, one for headache and one for vertigo. Interesting is the correlation between treatment discontinuations due to neuropsychiatric disorders and co-infection with hepatitis C virus, which has previously been associated with multiple neuropsychiatric disorders, in particular asthenia, depression and cognitive dysfunction. 31 Factors predisposing to the onset of neuropsychiatric disorders in patients on therapy in DTG have already been investigated 31, 32 and could be a starting point for further research and analysis within our cohort. The limitation of our study is that of not having collected any adverse events occurred during therapy not causing discontinuation of the regimen.
Regarding the improvement in immunological parameters, particularly interesting is the increase of the CD4/CD8 ratio, providing further evidence of the efficacy of this regimen also on the immunological level, with the limitation of the lack of a control group. As to the apparent worsening of renal function, the decrease in the glomerular filtration rate found in our population, predominantly in the first 48 weeks of follow-up, could probably be attributed to an intrinsic characteristic of dolutegravir. In fact, it inhibits the organic cation transporter 2 (OCT2), reducing the excretion at the tubular level of creatinine. 33 In agreement with previous results and other studies in the literature, 22, 34 the lipid profile of the patients in the study finds benefit from the simplification to the dual regimen with lamivudine and dolutegravir. In fact, both total cholesterol and triglyceride levels decrease during follow-up, especially in those patients who have a higher starting value at the time of the switch. It is to be noted that almost a third of the patients switched from another dual regimen with 3TC + bPI; in those patients the improvement in lipid profile was more pronounced.
In our experience, the two-drug regimen with lamivudine and dolutegravir in the context of therapeutic optimization with suppressed viremia has shown excellent virological efficacy and good tolerability.
Alongside these, the low presence of drug interactions and independence from food intake make this regime suitable for a very large population of HIV-infected patients, given the current trend of an aging population and the increase in incidence of comorbidity and polypharmacy. The strengths of our study are the sample size of our cohort, the real life setting and the duration of the follow-up; the limits are dictated, instead, by the retrospective nature of the study, the lack of a control arm and the lack of recording of some data, in particular adverse events that did not lead to suspension of the regime and further virological investigations (i.e. HIV-DNA).
Conclusions.
Lamivudine plus dolutegravir was effective in maintaining viral suppression in a large proportion of patients from a multicenter cohort of long term treated, HIV-1-positive patients with undetectable HIV-RNA at the time of switch. Even though further studies will be needed to assess the efficacy and safety of the regimen, in our opinion the patients' clinical history, including any co-infections with hepatitis viruses, and the patient's viro-immunological status at the time of therapeutic optimization should be carefully analyzed by the clinician when considering the switch to a dual therapy. 
